# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
1. Name and Address of Reporting Person * SAENGER BRADLEY				2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 306				3. Date of Earliest Transaction (Month/Day/Year) 06/14/2018							X Officer (give title below) Other (specify below)  Chief Financial Officer				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
	ORK, NY 1		(7:-)												
(City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deen Execution any (Month/D	n Date, if	Code (Instr. 8)	ction	(A) or Disposed o (D) (Instr. 3, 4 and 5)		of	Beneficial	ly Owned Following Γransaction(s)		Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
						Code	V	Amoun	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common value	Stock, \$0.	001 par	06/14/2018			P		300	Α .	\$ 4.1	3,079			D	
			Table II - D				cont the f d, Di	ained in form dis	n this for splays a o	m are curre eficial	e not requently valid	uired to re	nformation espond unle ntrol number	ess	EC 1474 (9- 02)
Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/\footnote{\text{Month/Day/\footnote{\text{V}}}}	3A. Deemed Execution Da	te, if Trai	nsaction e tr. 8)	5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ta		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners: Form of Derivati Security Direct (I	ve Ownership (Instr. 4)
				Co	de V	(A) (D)	Date		Expiration Date	Title	Amount or Number of Shares				
Repor	ting O	wners						,						•	
Reporting Owner Name / Address					Relationships										
, 0					Directo	r 10% Ov	vner	Officer			Oth	er			
SAENGER BRADLEY															

Chief Financial Officer

## **Signatures**

NEW YORK, NY 10022

/s/ Bradley Saenger	06/14/2018
Signature of Reporting Person	Date

509 MADISON AVENUE, SUITE 306

C/O TONIX PHARMACEUTICALS HOLDING CORP.

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

#### Remarks

1. Reporting person may be deemed to be a control person of this entity.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.